v3.26.1
Acquisitions - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Feb. 02, 2026
Jan. 02, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Sep. 30, 2025
Business Combination [Line Items]              
Acquisition and divestiture-related deal and integration expenses     $ 113,069,000 $ 52,838,000 $ 355,652,000 $ 190,930,000  
Remeasurement gain related to OneOncology acquisition         1,086,612,000 $ 0  
OneOncology              
Business Combination [Line Items]              
Retained ownership (as a percent) 8.00%            
RCA              
Business Combination [Line Items]              
Retained ownership (as a percent)   15.00%          
OneOncology              
Business Combination [Line Items]              
Total fair value consideration $ 7,387,100,000            
Cash 4,648,720,000            
Fair value of previously held equity method investment in OneOncology 1,934,224,000            
Settlement of a net receivable resulting from a pre-existing commercial relationship 51,990,000            
Goodwill expected to be deductible 2,420,000,000            
Acquisition and divestiture-related deal and integration expenses         54,300,000    
Acquisition date, revenue         820,000,000.0    
Remeasurement gain related to OneOncology acquisition         1,086,600,000    
Other intangible assets $ 3,062,000,000            
OneOncology | Trade Names              
Business Combination [Line Items]              
Useful Life 15 years            
OneOncology | Equity units              
Business Combination [Line Items]              
Contingent consideration $ 752,100,000            
RCA              
Business Combination [Line Items]              
Cash   $ 4,042,007,000          
Settlement of a net receivable resulting from a pre-existing commercial relationship   545,738,000          
Goodwill expected to be deductible   1,071,000,000          
Acquisition and divestiture-related deal and integration expenses   $ 65,100,000          
Ownership acquired (as a percent)   85.00%          
Other intangible assets   $ 178,000,000          
RCA | Trade Names              
Business Combination [Line Items]              
Other intangible assets   $ 178,000,000.0          
Useful Life   15 years          
RCA | Equity units              
Business Combination [Line Items]              
Contingent consideration   $ 694,400,000 957,600,000   957,600,000   $ 815,200,000
Acquisition and divestiture-related deal and integration expenses         143,600,000    
RCA | Equity units | Expense period              
Business Combination [Line Items]              
Expense period (in years)   1 year 6 months          
RCA | Predefined business objective              
Business Combination [Line Items]              
Contingent consideration   $ 393,100,000 412,600,000   412,600,000   $ 412,600,000
Potential payment   $ 500,000,000          
Estimated liability in Accrued Expenses and Other     300,000,000.0   300,000,000.0    
Estimated liability in Other Liabilities     $ 112,600,000   $ 112,600,000